Video

Dr. Winter on the Utility of PI3K Inhibitors in CLL

Allison Winter, MD, discusses the utility of PI3K inhibitors in chronic lymphocytic leukemia.

Allison Winter, MD, hematologist/medical oncologist, Cleveland Clinic, discusses the utility of PI3K inhibitors in chronic lymphocytic leukemia (CLL).

Patients who have progressed on prior BTK inhibitor therapy and venetoclax (Venclexta)-based therapy should be considered for a PI3K inhibitor as standard of care or within the context of a clinical trial, says Winter.

Investigational PI3K inhibitors, such as zandelisib (ME-401), are being evaluated in ongoing clinical trials for patients with relapsed/refractory CLL. Moreover, the agent appears to have a more favorable immune-related toxicity profile compared with approved PI3K inhibitors, such as idelalisib (Zydelig) and duvelisib (Copiktra), Winter explains. Additionally, the PI3K inhibitor umbralisib is being tested in combination with other agents in a number of ongoing clinical trials in this space, concludes Winter.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity